1. S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. (21st March 2018) Authors: van Vollenhoven, R; Hahn, B; Tsokos, G; Wagner, C; Lipsky, P; Hsu, B; Chevrier, M; Gordon, R; Triebel, M; Rose, S Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗